Lipo-ImmunoTech is at the forefront of developing innovative therapies targeting cancer and neurodegenerative diseases.
Cancer-specific Ceramide analog DRUGS
- Novel chemotherapeutics not traditionally targeted for therapy
- Attacks cancer cells through mitochondria
- Re-sensitization of cancer cells towards normal progression of cellular death
- Sphingolipid biology is a rising target for cancer treatment
- Multiple publications and early pre-clinical work already performed
- These compounds have indications to improve neurodegenerative disorders, such as Alzheimer’s Disease and ALS by improving mitochondrial quality control in neurons
Expansion of T cells for personalized tumor treatment
- Novel activation technology for T cell development from patient’s cells for superior anti-cancer functions
- Complementary system for CAR-T cell therapy
- T-cell therapy that does not need active genetic manipulation
- Ready for clinical trials because of the patient’s cells involved in therapy using TILs or CAR-T cells that we generate using a GMP-certified clean cell facility
State-of-the-Art Facilities
Our cutting-edge facilities provide the perfect environment for conducting research and developing new medical treatments. Equipped with the latest technology and equipment, we're able to achieve new levels of accuracy and precision.
Experienced Researchers
Our team of researchers has decades of experience in the medical field. With backgrounds in a wide range of specialties, we're able to approach research from a variety of perspectives and develop innovative solutions to complex problems.
Patient-Focused Research
At LIPO-IMMUNOTECH, we're committed to putting patients first. Our research is designed to improve patient outcomes and provide better treatment options for a wide range of medical conditions.
Collaborative Partnerships
We believe that the best results come from working together. That's why we collaborate with other research institutions, medical centers, and pharmaceutical companies to achieve our goals.
Innovative Solutions
We're always looking for new and innovative ways to approach medical research. Our team is constantly exploring new technologies, techniques, and approaches to achieve our goals.
Industry Recognition and CLINICAL TRIALS
Our groundbreaking research has earned us recognition as medical research and development leaders. Our research resulted in a phase I/II clinical trial (NCT05702853, Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL) for the treatment of patients with lymphoma at the Hollings Cancer Center using our CarT cell expansion technology. Please see the link below: